266 related articles for article (PubMed ID: 30448697)
21. A tumor-targeted Ganetespib-zinc phthalocyanine conjugate for synergistic chemo-photodynamic therapy.
Huang L; Wei G; Sun X; Jiang Y; Huang Z; Huang Y; Shen Y; Xu X; Liao Y; Zhao C
Eur J Med Chem; 2018 May; 151():294-303. PubMed ID: 29627724
[TBL] [Abstract][Full Text] [Related]
22. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
[TBL] [Abstract][Full Text] [Related]
23. Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature.
Bao R; Wang Y; Lai J; Zhu H; Zhao Y; Li S; Li N; Huang J; Yang Z; Wang F; Liu Z
Mol Pharm; 2019 Jan; 16(1):339-348. PubMed ID: 30452269
[TBL] [Abstract][Full Text] [Related]
24. Bcl-2 inhibitor uploaded upconversion nanophotosensitizers to overcome the photodynamic therapy resistance of cancer through adjuvant intervention strategy.
Liu X; Fan Z; Zhang L; Jin Z; Yan D; Zhang Y; Li X; Tu L; Xue B; Chang Y; Zhang H; Kong X
Biomaterials; 2017 Nov; 144():73-83. PubMed ID: 28823845
[TBL] [Abstract][Full Text] [Related]
25. Fabrication of ZnPc/protein nanohorns for double photodynamic and hyperthermic cancer phototherapy.
Zhang M; Murakami T; Ajima K; Tsuchida K; Sandanayaka AS; Ito O; Iijima S; Yudasaka M
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14773-8. PubMed ID: 18815374
[TBL] [Abstract][Full Text] [Related]
26. Mitochondrial Disruption Nanosystem Simultaneously Depressed Programmed Death Ligand-1 and Transforming Growth Factor-β to Overcome Photodynamic Immunotherapy Resistance.
Jiang X; Yi L; Li C; Wang H; Xiong W; Li Y; Zhou Z; Shen J
ACS Nano; 2024 Jan; 18(4):3331-3348. PubMed ID: 38227812
[TBL] [Abstract][Full Text] [Related]
27. Apoptosis and autophagy induced by pyropheophorbide-α methyl ester-mediated photodynamic therapy in human osteosarcoma MG-63 cells.
Huang Q; Ou YS; Tao Y; Yin H; Tu PH
Apoptosis; 2016 Jun; 21(6):749-60. PubMed ID: 27108344
[TBL] [Abstract][Full Text] [Related]
28. In vitro photodynamic therapy on human U251 glioma cells with a novel photosensitiser ZnPcS4-BSA.
Xu D; Ke Y; Jiang X; Cai Y; Peng Y; Li Y
Br J Neurosurg; 2010 Dec; 24(6):660-5. PubMed ID: 20707684
[TBL] [Abstract][Full Text] [Related]
29. Synergistic interaction of 5-aminolevulinic acid-based photodynamic therapy with simultaneous hyperthermia in an osteosarcoma tumor model.
Yanase S; Nomura J; Matsumura Y; Nagata T; Fujii T; Tagawa T
Int J Oncol; 2006 Aug; 29(2):365-73. PubMed ID: 16820878
[TBL] [Abstract][Full Text] [Related]
30. Self-reinforced photodynamic immunostimulator to downregulate and block PD-L1 for metastatic breast cancer treatment.
Qiu Z; Lu Z; Huang J; Zhong Y; Yan N; Kong R; Cheng H
Biomaterials; 2023 Dec; 303():122392. PubMed ID: 37984245
[TBL] [Abstract][Full Text] [Related]
31. A new antisarcoma strategy: multisubtype heat shock protein/peptide immunotherapy combined with PD-L1 immunological checkpoint inhibitors.
Li H; Sui X; Wang Z; Fu H; Wang Z; Yuan M; Liu S; Wang G; Guo Q
Clin Transl Oncol; 2021 Aug; 23(8):1688-1704. PubMed ID: 33792840
[TBL] [Abstract][Full Text] [Related]
32. Foscan and foslip based photodynamic therapy in osteosarcoma in vitro and in intratibial mouse models.
Meier D; Botter SM; Campanile C; Robl B; Gräfe S; Pellegrini G; Born W; Fuchs B
Int J Cancer; 2017 Apr; 140(7):1680-1692. PubMed ID: 27943293
[TBL] [Abstract][Full Text] [Related]
33. Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines.
Keremu A; Aimaiti A; Liang Z; Zou X
Cancer Chemother Pharmacol; 2019 Feb; 83(2):255-264. PubMed ID: 30430228
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy with L-arginine and α-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice.
He X; Lin H; Yuan L; Li B
Cancer Biol Ther; 2017 Feb; 18(2):94-100. PubMed ID: 28045576
[TBL] [Abstract][Full Text] [Related]
35. Investigation of in vitro PDT activities of zinc phthalocyanine immobilised TiO
Yurt F; Ince M; Colak SG; Ocakoglu K; Er O; Soylu HM; Gunduz C; Avci CB; Kurt CC
Int J Pharm; 2017 May; 524(1-2):467-474. PubMed ID: 28365390
[TBL] [Abstract][Full Text] [Related]
36. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy.
He C; Duan X; Guo N; Chan C; Poon C; Weichselbaum RR; Lin W
Nat Commun; 2016 Aug; 7():12499. PubMed ID: 27530650
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
38. Apoptosis of mouse MS-2 fibrosarcoma cells induced by photodynamic therapy with Zn (II)-phthalocyanine.
Zhou C; Shunji C; Jinsheng D; Junlin L; Jori G; Milanesi C
J Photochem Photobiol B; 1996 May; 33(3):219-23. PubMed ID: 8683397
[TBL] [Abstract][Full Text] [Related]
39. Hybrid Liquid Crystal Nanocarriers for Enhanced Zinc Phthalocyanine-Mediated Photodynamic Therapy.
Nag OK; Naciri J; Erickson JS; Oh E; Delehanty JB
Bioconjug Chem; 2018 Aug; 29(8):2701-2714. PubMed ID: 29990422
[TBL] [Abstract][Full Text] [Related]
40. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
